And right now, BTCY has 5 potential catalysts that could spark a possible breakout. Here's what you need to know...
No. 1 Potential BTCY Breakout Catalyst - Distribution On Amazon Could Be True Game-Changer
Biotricity Expands Distribution of New Bioheart Device on Amazon
New Heart Monitoring Solution Delivers Personalized Heart Health Insights Directly to Your Smartphone
Now Easy to Buy and Use: No Prescription Needed for Advanced Heart and Lifestyle Solution
REDWOOD CITY, CA / ACCESSWIRE / December 28, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced it has expanded the distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring technology used by physicians, on Amazon(dot)com.
Last month the company launched commercial sales of its Bioheart device. To improve availability and expand outreach, Biotricity has now listed it for purchase on Amazon(dot)com at: Bioheart on Amazon for $199 with a special introductory price of $149 for a limited time. You can view the Bioheart heart monitor in use here.
"We are aiming to transform the cardiac health marketplace and believe the Bioheart system will play an important role in that endeavor," said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, "The Bioheart device is an important component of our full spectrum, ‘virtual cardiac clinic' of mobile cardiac care and lifestyle solutions. It will be fully integrated with a growing number of cardiology practices through our cloud-based ‘Biosphere' ecosystem that we plan to fully roll out in 2022, allowing physicians to get a more holistic view of a patient's health."
"The ability to offer Bioheart on Amazon expands the availability for the public to easily access the benefits of this exciting technology," Dr. Waqaas added.
The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company's total addressable market by $1.24B. Heart conditions are intermittent, requiring long-term data collection for effective insights and lifestyle management. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots and long-term data collection.
Introducing a groundbreaking new capability, users can collect data for hours, days, weeks, months, and even years! They can create snapshots of rhythm data by reviewing past data and marking it for personal records. These are first-of-its-kind features that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.
Read the full article here.
No. 2 Potential BTCY Breakout Catalyst - Bioheart Heart Monitor Product Now Available
Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor
Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone
REDWOOD CITY, Calif., November 10, 2021--(BUSINESS WIRE)--Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. Showcased in prototype form at CES 2020, Bioheart has shipped to preorder customers and is now available for purchase at www(dot)bioheart(dot)com.
The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B, the global heart rate monitoring market. "Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey," said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.
Heart conditions are intermittent, requiring long term data collection for effective insights. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots. Introducing a groundbreaking new capability, users can create snapshots of rhythm data by reviewing past data and marking it for personal records. This is a first-of-its-kind feature that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.
Bioheart incorporates the Company’s proprietary advanced heart technology, combined with powerful analytics and continuous rhythm monitoring, to help individuals understand and improve their heart health. It provides 24/7 electrical heart rhythm monitoring and recording with three different views of the heart, which can be streamed live on the Bioheart smartphone app. Bioheart is the most accurate heart monitor available without a prescription.
"Bioheart combines unparalleled accuracy in a heart monitoring device with continuous data, advanced heart health insights, and powerful features tailored to individuals at risk for heart disease or who want precise data for performance tracking, optimization and preventative cardiac wellness," said Dr. Al-Siddiq. "Bioheart furthers Biotricity’s mission of developing revolutionary healthcare solutions that help engage and empower individuals to take control of their health, starting with the deadliest chronic disease and one of healthcare’s largest cost drivers: cardiac disease."
"Bioheart has the potential to make an immediate, life-changing impact for those who use it," added Dr. Al-Siddiq. "As a direct manufacturer, we’re thrilled to have been able to accelerate our market delivery to the general market in less than a year, ahead of schedule and in time for the busy holiday gifting season."
Read the full article here.
No. 3 Potential BTCY Breakout Catalyst - Strong Balance Sheet And Revenue Growth Announcement
Biotricity Releases Fiscal 2022 Second Quarter Fin-an-cial Results
- Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth
- Strongest balance sheet since inception
REDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 /Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced fin-an-cial results for its 2022 fiscal year's second quarter ended September 30, 2021.
"This was a historic quarter with our recent listing on the Nasdaq, in which we strengthened our balance sheet, and introduced our plans for Biokit and its commercial launch in the first quarter of calendar 2022," stated Dr. Waqaas Al-Siddiq, CEO and founder of Biotricity. "We have disclosed several other state-of-the-art remote cardiac monitoring devices and software apps in our development pipeline - all of which are planned for commercialization in 2022, pending FDA clearance where required."
Read the full article here.
No. 4 Potential BTCY Breakout Catalyst - Key Technicals Could Signal Possible Near Term Healthy Reversal
As of close on Friday, Barchart was reporting this profile to have several oversold leaning technicals.
These technicals could be signaling a healthy reversal in the near term for BTCY.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Now, here are some key technicals (as of close Friday) that could signal BTCY to be leaning oversold and on the verge of a potential reversal.
- 9-Day Relative Strength Index: 37.72%
- 14-Day Relative Strength Index: 38.66%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 20-Day Raw Stochastic: 13.39%
- 20-Day Williams %R: 86.61%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
No. 5 Potential BTCY Breakout Catalyst - Major Price Targets From 4 Different Analysts/Firms
Since July 1st 2021, four different analysts have provided price targets of either $6.00 or $7.00 according to MarketBeat's website. Check them out: